Free tool
FAERS Monitor: Gastrografin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011245 or its brand name (Gastrografin, Diatrizoate Meglumine, Diatrizoate Sodium). Reports on generic versions are filed under their own applications.
Reports
372
Serious
260
70% of reports
Hospitalization
149
Death reported
54
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria31
- diarrhoea27
- nausea24
- vomiting23
- no adverse event22
- pruritus19
- drug ineffective17
- off label use17
- dyspnoea16
- rash13
- sepsis12
- hypotension11
- abdominal pain10
- anaemia10
- aspiration10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 9 |
| 2006 | 12 |
| 2007 | 7 |
| 2008 | 27 |
| 2009 | 15 |
| 2010 | 27 |
| 2011 | 22 |
| 2012 | 20 |
| 2013 | 17 |
| 2014 | 16 |
| 2015 | 20 |
| 2016 | 30 |
| 2017 | 22 |
| 2018 | 22 |
| 2019 | 19 |
| 2020 | 13 |
| 2021 | 25 |
| 2022 | 17 |
| 2023 | 14 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,787 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aspirationSignal | 10 | 51.7 | 28.0 | 447 |
| urticariaSignal | 31 | 10.5 | 7.5 | 258 |
| no adverse eventSignal | 22 | 6.9 | 4.6 | 105 |
| sepsisSignal | 12 | 6.1 | 3.5 | 46 |
| hypotensionSignal | 11 | 3.1 | 1.7 | 14 |
| anaemiaSignal | 10 | 3.0 | 1.6 | 11 |
| pruritusSignal | 19 | 2.8 | 1.8 | 21 |
| vomitingSignal | 23 | 2.8 | 1.9 | 25 |
| abdominal painSignal | 10 | 2.4 | 1.3 | 7 |
| diarrhoeaSignal | 27 | 2.4 | 1.6 | 21 |
| nausea | 24 | 1.7 | 1.2 | 7 |
| rash | 13 | 1.7 | 1.0 | 3 |
| dyspnoea | 16 | 1.6 | 1.0 | 3 |
| off label use | 17 | 1.1 | 0.7 | 0 |
| drug ineffective | 17 | 0.7 | 0.5 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.